Cancer Biotherapy and Radiopharmaceuticals
Mary Ann Liebert Inc.
United States
journal
SJR by Edition
Subject Categories
- Radiology, Nuclear Medicine and ImagingQ2
- Medicine (miscellaneous)Q3
- OncologyQ3
- PharmacologyQ3
- Cancer ResearchQ4
Areas: Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics
Most published research topics
Source: OpenAlex
Publication Statistics
Documents per Year
Detailed Information
ISSN
1084-9785, 1557-8852
SJR Best Quartile
Q2
Region
Northern America
Citations per Document (2 years)
1.94
References per Document
49.26
Coverage
1996-2026
Scope
Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Cancer Biotherapy and Radiopharmaceuticals coverage includes: Antibody drug conjugates Fusion toxins and immunotoxins Nanoparticle therapy Vascular therapy Inhibitors of proliferation signaling pathways.
Metrics from SCImago Journal Rank 2025. View on SCImago